Paul Parren

Paul Parren

Company: Lava Therapeutics

Job title: Head of R&D


Panel Discussion: Sharing Perspectives on the Application & Attractiveness of Gamma Delta T Therapy in a Competitive Treatment Landscape 11:30 am

Discussing the pros and cons of gamma delta T therapies as a treatment option for patients vs. standard therapy and analogous immune cell therapies Communicating the key differentiators in the clinic that make gamma delta cells an attractive treatment option Outlining roadblocks to the uptake of gamma delta therapies in the clinic for developers to…Read more

day: Day 2 am track b

Developing Highly Potent Bispecific T Cell Engagers for Targeted Activation of Vgamma9Vdelta2 T Cells 9:10 am

Outlining the preclinical development and mechanism of action Demonstrating the activation and expansion of gamma delta T cells eliciting broad immune activation, and tumor-preferential killing Bringing bispecific gamma-delta T cell engagers to the clinic in hematology and solid tumor indications Providing updates on safety, tolerability, pharmacokinetics, pharmacodynamics in Phase I clinical studiesRead more

day: Day Two

Industry Leader’s Fireside Chat 8:45 am

Contrasting therapeutic approaches to harness gamma delta T cells and provide an overview of the development landscape Identifying the greatest areas of opportunity and key challenges to the industry in gamma delta T cell development Discussing next steps in development, from combination approaches to gaining traction in the solid tumor spaceRead more

day: Day One

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.